INSMED INC (INSM)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for INSM
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| INSM | Director; Chair of the Board; Chair and CEO; Chair and Chief Executive Officer | 57 | ["20 years of executive experience in the life sciences industry", "30 years of experience in the pharmaceutical and finance industries", "Pivotal role in re-orienting Aegerion's strategy", "Experience with financing, orphan drug development and commercialization", "International business development", "Responsible for corporate strategy", "Provides direction and leadership", "Developing corporate mission and objectives", "Providing direction and leadership", "Leading U.S. commercial organization"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Age: 57 Director Since: September 2012 Chair of the Board Since: November 2018 CEO Since: September 2012 Consultant to the Board From: June - September 2012 Current Public Board Service: Chair of the Board of Directors, NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) Qualifications: Mr. Lewis has 20 years of executive experience in the life sciences industry and a track record of success for 30 years in the pharmaceutical and finance industries both in the United States and internationally. During his tenure at Aegerion, Mr. Lewis played a pivotal role in re-orienting the company s strategy to focus on rare disease indications, enabling Aegerion to conduct a successful initial public offering in 2010. The Board believes that Mr. Lewis brings significant qualifications to his role as Chair due to his experience as our CEO since 2012 and his experience as an executive at Aegerion. His professional experience offers the Board significant insights and experience with financing, orphan drug development and commercialization, and international business development. Education: Oberlin College - B.A. Case Western Reserve University - M.B.A. Case Western Reserve University - J.D. Career Highlights: Insmed Incorporated (Nasdaq: INSM) (2012 - present) Chair and CEO (2018 - present) President and CEO (2012 - 2018) Aegerion Pharmaceuticals, Inc. (Formerly, Nasdaq: AEGR) (2005 - 2011) Co-founder President Chief Financial Officer Wells Fargo & Co. (2002 - 2004) Robertson Stephens Capital (2000 - 2002) JP Morgan Chase & Co. (1995 - 2000) Foreign Service for the U.S. Government (1989 - 1992)